These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27181545)

  • 41. Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice.
    Sekine M; Kubuki Y; Kameda T; Takeuchi M; Toyama T; Kawano N; Maeda K; Sato S; Ishizaki J; Kawano H; Kamiunten A; Akizuki K; Tahira Y; Shimoda H; Shide K; Hidaka T; Kitanaka A; Yamashita K; Matsuoka H; Shimoda K
    Eur J Haematol; 2017 May; 98(5):501-507. PubMed ID: 28152225
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance.
    Ishitsuka K; Yurimoto S; Kawamura K; Tsuji Y; Iwabuchi M; Takahashi T; Tobinai K
    Int J Hematol; 2017 Oct; 106(4):522-532. PubMed ID: 28597329
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Galectin-9 as a Predictive Marker for the Onset of Immune-Related Adverse Effects Associated with Anti-CCR4 MoAb Therapy in Patients with Adult T Cell Leukemia.
    Mohammed TO; Chagan-Yasutan H; Ashino Y; Nakayama W; Takahashi Y; Shimomura T; Fujimoto T; Watanabe Y; Niki T; Suzushima H; Hattori T
    Tohoku J Exp Med; 2017 Mar; 241(3):201-208. PubMed ID: 28321034
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biology and treatment of HTLV-1 associated T-cell lymphomas.
    Tsukasaki K; Tobinai K
    Best Pract Res Clin Haematol; 2013 Mar; 26(1):3-14. PubMed ID: 23768636
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adult T Cell Leukemia-Lymphoma (ATL): State of the Art.
    Phillips AA; Harewood JCK
    Curr Hematol Malig Rep; 2018 Aug; 13(4):300-307. PubMed ID: 30047026
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study.
    Ishida T; Jo T; Takemoto S; Suzushima H; Uozumi K; Yamamoto K; Uike N; Saburi Y; Nosaka K; Utsunomiya A; Tobinai K; Fujiwara H; Ishitsuka K; Yoshida S; Taira N; Moriuchi Y; Imada K; Miyamoto T; Akinaga S; Tomonaga M; Ueda R
    Br J Haematol; 2015 Jun; 169(5):672-82. PubMed ID: 25733162
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Late onset toxic epidermal necrolysis induced by mogamulizumab, an anti-CC chemokine receptor 4 antibody for the treatment of adult T-cell leukaemia/lymphoma.
    Shiratori S; Ohhigashi H; Ito S; Kudo K; Adachi M; Minamimoto T; Kato J; Osai Y; Tsutsumi Y; Teshima T
    Hematol Oncol; 2017 Mar; 35(1):138-140. PubMed ID: 26177633
    [No Abstract]   [Full Text] [Related]  

  • 48. Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia / lymphoma.
    Ishida T; Ito A; Sato F; Kusumoto S; Iida S; Inagaki H; Morita A; Akinaga S; Ueda R
    Cancer Sci; 2013 May; 104(5):647-50. PubMed ID: 23360455
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Successful treatment of a patient with adult T cell leukemia/lymphoma using anti-CC chemokine receptor 4 monoclonal antibody mogamulizumab followed by allogeneic hematopoietic stem cell transplantation.
    Motohashi K; Suzuki T; Kishimoto K; Numata A; Nakajima Y; Tachibana T; Ohshima R; Kuwabara H; Tanaka M; Tomita N; Ishigatsubo Y; Fujisawa S
    Int J Hematol; 2013 Aug; 98(2):258-60. PubMed ID: 23801427
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of Engineered T Cells Expressing a Chimeric CD16-CD3ΞΆ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia.
    Tanaka H; Fujiwara H; Ochi F; Tanimoto K; Casey N; Okamoto S; Mineno J; Kuzushima K; Shiku H; Sugiyama T; Barrett AJ; Yasukawa M
    Clin Cancer Res; 2016 Sep; 22(17):4405-16. PubMed ID: 27091408
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fatal pneumonia and viremia due to human parainfluenza virus type 1 in a patient with adult T-cell leukemia-lymphoma treated with mogamulizumab.
    Tamaki K; Kinjo T; Aoyama H; Tomoyose T; Nakachi S; Hanashiro T; Shimabukuro N; Tedokon I; Morichika K; Nishi Y; Taira N; Fujita J; Yoshimi N; Fukushima T; Masuzaki H
    J Infect Chemother; 2015 Nov; 21(11):820-3. PubMed ID: 26231316
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CCR7 alterations associated with inferior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment.
    Sakamoto Y; Ishida T; Masaki A; Murase T; Ohtsuka E; Takeshita M; Muto R; Iwasaki H; Ito A; Kusumoto S; Nakano N; Tokunaga M; Yonekura K; Tashiro Y; Iida S; Utsunomiya A; Ueda R; Inagaki H
    Hematol Oncol; 2022 Dec; 40(5):876-884. PubMed ID: 36043457
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma.
    Nakashima J; Imaizumi Y; Taniguchi H; Ando K; Iwanaga M; Itonaga H; Sato S; Sawayama Y; Hata T; Yoshida S; Moriuchi Y; Miyazaki Y
    Int J Hematol; 2018 Nov; 108(5):516-523. PubMed ID: 30032392
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
    Yamamoto K; Utsunomiya A; Tobinai K; Tsukasaki K; Uike N; Uozumi K; Yamaguchi K; Yamada Y; Hanada S; Tamura K; Nakamura S; Inagaki H; Ohshima K; Kiyoi H; Ishida T; Matsushima K; Akinaga S; Ogura M; Tomonaga M; Ueda R
    J Clin Oncol; 2010 Mar; 28(9):1591-8. PubMed ID: 20177026
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Mogamulizumab for the treatment of ATL and PTCL].
    Tsukasaki K
    Gan To Kagaku Ryoho; 2015 May; 42(5):553-7. PubMed ID: 26054089
    [No Abstract]   [Full Text] [Related]  

  • 56. [Long-term remission with mogamulizumab monotherapy in a patient with refractory adult T-cell leukemia-lymphoma].
    Nakaya Y; Tsutsumi M; Fuseya H; Horiuchi M; Yoshimura T; Hayashi Y; Kanashima H; Nakao T; Yamane T
    Rinsho Ketsueki; 2018; 59(3):326-328. PubMed ID: 29618693
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.
    Antoniu SA
    Curr Opin Mol Ther; 2010 Dec; 12(6):770-9. PubMed ID: 21154168
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CCR4 is rarely expressed in CCR4-mutated T/NK-cell lymphomas other than adult T-cell leukemia/lymphoma.
    Sakamoto Y; Fujii K; Murase S; Nakano S; Masaki A; Murase T; Kusumoto S; Iida S; Utsunomiya A; Ueda R; Ishida T; Inagaki H
    Int J Hematol; 2019 Oct; 110(4):389-392. PubMed ID: 31468320
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epstein-Barr virus-related diffuse large B-cell lymphoma in mogamulizumab-treated adult T-cell leukemia with incomplete T-cell reconstitution.
    Kamachi K; Shindo T; Miyahara M; Kitaura K; Akashi M; Shin-I T; Suzuki R; Oshima K; Kimura S
    Int J Hematol; 2019 Feb; 109(2):221-227. PubMed ID: 30368656
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Administration of an anti-CC chemokine receptor 4 monoclonal antibody, mogamulizumab, before allogeneic bone marrow transplantation for adult T-cell leukemia/lymphoma.
    Haji S; Kiyasu J; Choi I; Suehiro Y; Toyoda K; Tsuda M; Takamatsu A; Nakashima Y; Miyoshi H; Shiratsuchi M; Yamasaki S; Uike N; Abe Y
    Bone Marrow Transplant; 2016 Mar; 51(3):432-4. PubMed ID: 26524267
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.